ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Application site reaction,Application site reactions,Administration site reactions,Genrl,N
1,2,Lip oedema,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
2,1,Bronchospasm,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
2,2,Respiratory distress,Breathing abnormalities,Respiratory disorders NEC,Resp,N
3,1,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
3,2,Swollen tongue,Tongue signs and symptoms,Tongue conditions,Gastr,N
4,1,Burning sensation,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
4,2,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
4,3,Stomatitis,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
5,1,Application site rash,Application site reactions,Administration site reactions,Genrl,N
5,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
5,3,Tremor,Tremor (excl congenital),Movement disorders (incl parkinsonism),Nerv,N
5,4,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
6,1,Anaphylactic reaction,Anaphylactic and anaphylactoid responses,Allergic conditions,Immun,N
